Icon Plc (NASDAQ:ICLR) Receives Average Recommendation of “Hold” from Analysts

Icon Plc (NASDAQ:ICLR) has received a consensus recommendation of “Hold” from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $145.6667.

Several research firms have commented on ICLR. Leerink Partners set a $125.00 target price on shares of Icon in a research report on Monday, May 4th. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Jefferies Financial Group set a $135.00 target price on shares of Icon and gave the stock a “buy” rating in a research report on Monday, February 23rd. BMO Capital Markets upgraded shares of Icon from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $100.00 to $130.00 in a research report on Thursday, March 26th. Finally, Royal Bank Of Canada began coverage on shares of Icon in a research report on Monday. They issued a “sector perform” rating and a $123.00 target price for the company.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $116.57 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a fifty-two week low of $66.57 and a fifty-two week high of $211.00. The firm has a 50-day simple moving average of $110.21 and a 200 day simple moving average of $142.99. The company has a market cap of $9.41 billion, a PE ratio of 15.77, a P/E/G ratio of 3.01 and a beta of 1.23.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sanctuary Advisors LLC grew its position in Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after purchasing an additional 56 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the last quarter. New Wave Wealth Advisors LLC grew its position in Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the last quarter. Signaturefd LLC grew its position in Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of Icon by 0.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after acquiring an additional 93 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.